Californian specialty drugmaker Amphastar Pharmaceuticals (Nasdaq: AMPH) has bought Baqsimi (glucagon) from Eli Lilly (NYSE: LLY), in a deal worth over a billion dollars.
The Rancho Cucamonga-based company is focused on developing both generic and proprietary products which are injectable, intranasal, or inhalable.
As the first and only nasally-administered glucagon for the treatment of severe hypoglycemia in people with diabetes, Baqsimi will fit into the company’s portfolio very well.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze